DossierENTITY

pipeline premium

Coverage of pipeline premium in the Nexus archive.

Earliest in view: Jul 11 · 05:00 UTCMost recent: Jul 11 · 05:00 UTC

Co-mentioned in this coverage

Recent coverage

BUSINESSJul 11 · 05:00 UTCCNBC TOP
AstraZeneca's trial flop raises a bigger question: Is its pipeline premium becoming more vulnerable?
AstraZeneca's recent trial failure has raised concerns about the vulnerability of its pipeline premium. The company has been valued highly among European pharma firms based on consistent results.